Seeing further.

THAT’S OUR TARGET

We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.

News

Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200

Idera receives $15 million upfront, with potential IMO-9200-related milestone payments totaling up… Read more 

Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera to Present at the Stifel 2016 Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Learn More

Events

Sat, 10 Dec 2016 16:03:04 GMT

Idera Pharmaceuticals, Inc. Calendar Events

A Collection of Idera Pharmaceuticals, Inc. Calendar Events… Read more 

Learn More